Nitric oxide in respiratory diseases.
The formation and modulation of nitric oxide (NO) in the lungs is reviewed. Its beneficial and deleterious roles in airways diseases, including asthma, chronic obstructive pulmonary disease, and cystic fibrosis, and in animal models is discussed. The pharmacological effects of agents that modulate NO production or act as NO donors are described. The clinical pharmacology of these agents is described and the therapeutic potential for their use in airways disease is considered.
Nevin
B J
BJ
Division of Pharmacology, Welsh School of Pharmacy, Cardiff University, Cathays Park, Cardiff, CF10 3XF, UK.
Broadley
K J
KJ
D000818:Animals; D004347:Drug Interactions; D006801:Humans; D018482:Muscle, Skeletal / Q000187:drug effects; D009569:Nitric Oxide / Q000096:biosynthesis / Q000502:physiology / Q000627:therapeutic use; D020030:Nitric Oxide Donors / Q000494:pharmacology; D012140:Respiratory Tract Diseases / Q000188:drug therapy*; D026403:S-Nitrosothiols / Q000494:pharmacology
D020030:Nitric Oxide Donors; D026403:S-Nitrosothiols; D009569:Nitric Oxide